Reported Earnings • Jun 02
Full year 2026 earnings released: EPS: ₹3.83 (vs ₹1.54 loss in FY 2025) Full year 2026 results: EPS: ₹3.83 (up from ₹1.54 loss in FY 2025). Revenue: ₹105.9m (up 57% from FY 2025). Net income: ₹17.6m (up ₹24.7m from FY 2025). Profit margin: 17% (up from net loss in FY 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Ankündigung • May 06
Caprolactam Chemicals Limited to Report Q4, 2026 Results on May 30, 2026 Caprolactam Chemicals Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026 New Risk • Mar 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹88m revenue, or US$961k). Market cap is less than US$10m (₹301.5m market cap, or US$3.28m). Ankündigung • Jan 27
Caprolactam Chemicals Limited to Report Q3, 2026 Results on Feb 13, 2026 Caprolactam Chemicals Limited announced that they will report Q3, 2026 results on Feb 13, 2026 New Risk • Dec 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹88m revenue, or US$982k). Market cap is less than US$10m (₹291.0m market cap, or US$3.24m). Minor Risk Share price has been volatile over the past 3 months (7.0% average weekly change). New Risk • Nov 16
New major risk - Revenue and earnings growth Earnings have declined by 5.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Earnings have declined by 5.5% per year over the past 5 years. Revenue is less than US$1m (₹89m revenue, or US$998k). Market cap is less than US$10m (₹220.4m market cap, or US$2.49m). Reported Earnings • Nov 16
Second quarter 2026 earnings released: EPS: ₹0.27 (vs ₹0.09 in 2Q 2025) Second quarter 2026 results: EPS: ₹0.27 (up from ₹0.09 in 2Q 2025). Revenue: ₹23.9m (up 39% from 2Q 2025). Net income: ₹1.26m (up 215% from 2Q 2025). Profit margin: 5.3% (up from 2.3% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance. Ankündigung • Oct 24
Caprolactam Chemicals Limited to Report First Half, 2026 Results on Nov 14, 2025 Caprolactam Chemicals Limited announced that they will report first half, 2026 results on Nov 14, 2025 Ankündigung • Aug 18
Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2025 Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2025, at 10:30 Indian Standard Time. Reported Earnings • Aug 16
First quarter 2026 earnings released: EPS: ₹0.79 (vs ₹0.58 loss in 1Q 2025) First quarter 2026 results: EPS: ₹0.79 (up from ₹0.58 loss in 1Q 2025). Revenue: ₹25.7m (up 128% from 1Q 2025). Net income: ₹3.62m (up ₹6.28m from 1Q 2025). Profit margin: 14% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Ankündigung • Aug 09
Caprolactam Chemicals Limited to Report Q1, 2026 Results on Aug 14, 2025 Caprolactam Chemicals Limited announced that they will report Q1, 2026 results on Aug 14, 2025 New Risk • Jun 02
New major risk - Revenue and earnings growth Earnings have declined by 1.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 1.3% per year over the past 5 years. Revenue is less than US$1m (₹67m revenue, or US$790k). Market cap is less than US$10m (₹187.7m market cap, or US$2.20m). Reported Earnings • Jun 02
Full year 2025 earnings released: ₹1.54 loss per share (vs ₹0.43 profit in FY 2024) Full year 2025 results: ₹1.54 loss per share (down from ₹0.43 profit in FY 2024). Revenue: ₹67.5m (down 3.0% from FY 2024). Net loss: ₹7.09m (down 459% from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Ankündigung • May 17
Caprolactam Chemicals Limited to Report Q4, 2025 Results on May 30, 2025 Caprolactam Chemicals Limited announced that they will report Q4, 2025 results on May 30, 2025 New Risk • Apr 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.0x net interest cover). Earnings have declined by 5.9% per year over the past 5 years. Revenue is less than US$1m (₹66m revenue, or US$771k). Market cap is less than US$10m (₹188.0m market cap, or US$2.21m). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change). New Risk • Mar 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.0x net interest cover). Share price has been highly volatile over the past 3 months (9.5% average weekly change). Earnings have declined by 5.9% per year over the past 5 years. Revenue is less than US$1m (₹66m revenue, or US$753k). Market cap is less than US$10m (₹190.0m market cap, or US$2.18m). Reported Earnings • Feb 16
Third quarter 2025 earnings released: ₹0.07 loss per share (vs ₹0.35 loss in 3Q 2024) Third quarter 2025 results: ₹0.07 loss per share (improved from ₹0.35 loss in 3Q 2024). Revenue: ₹23.0m (up 55% from 3Q 2024). Net loss: ₹317.0k (loss narrowed 81% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Ankündigung • Jan 28
Caprolactam Chemicals Limited to Report Q3, 2025 Results on Feb 14, 2025 Caprolactam Chemicals Limited announced that they will report Q3, 2025 results on Feb 14, 2025 New Risk • Dec 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m (₹58m revenue, or US$674k). Market cap is less than US$10m (₹287.0m market cap, or US$3.36m). Reported Earnings • Nov 13
Second quarter 2025 earnings released: EPS: ₹0.09 (vs ₹0.12 loss in 2Q 2024) Second quarter 2025 results: EPS: ₹0.09 (up from ₹0.12 loss in 2Q 2024). Revenue: ₹17.1m (down 13% from 2Q 2024). Net income: ₹399.0k (up ₹959.0k from 2Q 2024). Profit margin: 2.3% (up from net loss in 2Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Ankündigung • Nov 05
Caprolactam Chemicals Limited to Report Q2, 2025 Results on Nov 12, 2024 Caprolactam Chemicals Limited announced that they will report Q2, 2025 results on Nov 12, 2024 Ankündigung • Sep 24
Caprolactam Chemicals Limited Announces Appointment of Directors Caprolactam Chemicals Limited announced that at its AGM held on September 24, 2024, shareholders approved the appointment of Mr. Viren Jaysukhlal lasani as lndependent Director and Mr. Kamlesh Damji Joisher as Independent Director, not liable to retire by rotation, for the first term of 5 years. Ankündigung • Aug 29
Caprolactam Chemicals Limited, Annual General Meeting, Sep 24, 2024 Caprolactam Chemicals Limited, Annual General Meeting, Sep 24, 2024, at 11:30 Indian Standard Time. Reported Earnings • Aug 14
First quarter 2025 earnings released First quarter 2025 results: Revenue: ₹11.2m (down 44% from 1Q 2024). Net loss: ₹2.66m (down 319% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Ankündigung • Jul 18
Caprolactam Chemicals Limited to Report Q1, 2025 Results on Aug 12, 2024 Caprolactam Chemicals Limited announced that they will report Q1, 2025 results on Aug 12, 2024 Reported Earnings • May 29
Full year 2024 earnings released: EPS: ₹0.43 (vs ₹5.54 in FY 2023) Full year 2024 results: EPS: ₹0.43 (down from ₹5.54 in FY 2023). Revenue: ₹71.4m (down 28% from FY 2023). Net income: ₹1.97m (down 92% from FY 2023). Profit margin: 2.8% (down from 26% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Feb 10
Third quarter 2024 earnings released: ₹0.35 loss per share (vs ₹1.60 profit in 3Q 2023) Third quarter 2024 results: ₹0.35 loss per share (down from ₹1.60 profit in 3Q 2023). Revenue: ₹14.9m (down 37% from 3Q 2023). Net loss: ₹1.63m (down 122% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Ankündigung • Jan 18
Caprolactam Chemicals Limited to Report Nine Months, 2024 Results on Feb 09, 2024 Caprolactam Chemicals Limited announced that they will report nine months, 2024 results on Feb 09, 2024 New Risk • Nov 20
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.8x net interest cover). Market cap is less than US$10m (₹293.8m market cap, or US$3.53m). Minor Risk Revenue is less than US$5m (₹86m revenue, or US$1.0m). Ankündigung • Nov 04
Caprolactam Chemicals Limited to Report Q2, 2024 Results on Nov 11, 2023 Caprolactam Chemicals Limited announced that they will report Q2, 2024 results on Nov 11, 2023 Ankündigung • Sep 02
Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2023 Caprolactam Chemicals Limited, Annual General Meeting, Sep 25, 2023, at 11:00 Indian Standard Time. Location: B/31, MIDC, Mahad, Distt. - Raigad. Maharashtra- 402302 Raigad Maharashtra India Agenda: To consider and adopt the Annual Audited Financial Statements of the Company for the financial year ended 315t March, 2023 together with the reports of the Board of Directors and Auditors thereon; and to consider other issues. Ankündigung • Aug 03
Caprolactam Chemicals Limited to Report Q1, 2024 Results on Aug 12, 2023 Caprolactam Chemicals Limited announced that they will report Q1, 2024 results on Aug 12, 2023 New Risk • Jul 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.9% average weekly change). High level of non-cash earnings (45% accrual ratio). Market cap is less than US$10m (₹278.2m market cap, or US$3.39m). Minor Risk Revenue is less than US$5m (₹98m revenue, or US$1.2m). Valuation Update With 7 Day Price Move • Jun 27
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹54.87, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 127% over the past three years. Reported Earnings • May 31
Full year 2023 earnings released: EPS: ₹5.54 (vs ₹2.79 loss in FY 2022) Full year 2023 results: EPS: ₹5.54 (up from ₹2.79 loss in FY 2022). Revenue: ₹98.6m (up 376% from FY 2022). Net income: ₹25.5m (up ₹38.3m from FY 2022). Profit margin: 26% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year and the company’s share price has also increased by 43% per year. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹54.69, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 186% over the past three years. Reported Earnings • Feb 16
Third quarter 2023 earnings released: EPS: ₹1.60 (vs ₹1.76 loss in 3Q 2022) Third quarter 2023 results: EPS: ₹1.60 (up from ₹1.76 loss in 3Q 2022). Revenue: ₹23.7m (up ₹22.2m from 3Q 2022). Net income: ₹7.35m (up ₹15.4m from 3Q 2022). Profit margin: 31% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings. Ankündigung • Feb 02
Caprolactam Chemicals Limited to Report First Half, 2023 Results on Feb 14, 2023 Caprolactam Chemicals Limited announced that they will report first half, 2023 results on Feb 14, 2023 Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Additional Independent Non-Executive Director Poonam Bhanushali was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Nov 03
Caprolactam Chemicals Limited to Report Q2, 2023 Results on Nov 14, 2022 Caprolactam Chemicals Limited announced that they will report Q2, 2023 results on Nov 14, 2022 Reported Earnings • Sep 04
Full year 2022 earnings released: ₹2.79 loss per share (vs ₹1.41 profit in FY 2021) Full year 2022 results: ₹2.79 loss per share (down from ₹1.41 profit in FY 2021). Revenue: ₹24.7m (down 61% from FY 2021). Net loss: ₹12.8m (down 297% from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 176 percentage points per year, which is a significant difference in performance. Ankündigung • Aug 07
Caprolactam Chemicals Limited to Report Q1, 2023 Results on Aug 13, 2022 Caprolactam Chemicals Limited announced that they will report Q1, 2023 results on Aug 13, 2022 Ankündigung • May 06
Caprolactam Chemicals Limited to Report Q4, 2022 Results on May 30, 2022 Caprolactam Chemicals Limited announced that they will report Q4, 2022 results on May 30, 2022 Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Additional Independent Non-Executive Director Poonam Bhanushali was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 17
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: ₹1.76 loss per share (down from ₹1.94 profit in 3Q 2021). Revenue: ₹1.78m (down 93% from 3Q 2021). Net loss: ₹8.10m (down 191% from profit in 3Q 2021). Revenue was in line with analyst estimates. Ankündigung • Feb 02
Caprolactam Chemicals Limited to Report Q3, 2022 Results on Feb 14, 2022 Caprolactam Chemicals Limited announced that they will report Q3, 2022 results on Feb 14, 2022 Reported Earnings • Nov 18
Second quarter 2022 earnings released: ₹0.75 loss per share (vs ₹0.49 profit in 2Q 2021) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹5.96m (down 59% from 2Q 2021). Net loss: ₹3.43m (down 252% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 89% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹57.50, the stock trades at a trailing P/E ratio of 41x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 464% over the past three years. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improved over the past week After last week's 18% share price gain to ₹68.80, the stock trades at a trailing P/E ratio of 48.7x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 568% over the past three years. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹88.05, the stock trades at a trailing P/E ratio of 62.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 739% over the past three years. Reported Earnings • Jul 06
Full year 2021 earnings released: EPS ₹1.41 (vs ₹2.07 in FY 2020) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹63.1m (down 3.1% from FY 2020). Net income: ₹6.51m (down 32% from FY 2020). Profit margin: 10% (down from 15% in FY 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 117% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 12
Investor sentiment improved over the past week After last week's 16% share price gain to ₹35.40, the stock trades at a trailing P/E ratio of 53.2x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 251% over the past three years. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improved over the past week After last week's 21% share price gain to ₹35.90, the stock trades at a trailing P/E ratio of 53.9x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 256% over the past three years. Valuation Update With 7 Day Price Move • Mar 02
Investor sentiment improved over the past week After last week's 16% share price gain to ₹26.25, the stock is trading at a trailing P/E ratio of 39.4x, up from the previous P/E ratio of 33.9x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 135%. Is New 90 Day High Low • Mar 01
New 90-day high: ₹25.00 The company is up 41% from its price of ₹17.70 on 01 December 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improved over the past week After last week's 27% share price gain to ₹24.05, the stock is trading at a trailing P/E ratio of 36.1x, up from the previous P/E ratio of 28.5x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 95%. Is New 90 Day High Low • Feb 04
New 90-day high: ₹20.90 The company is up 31% from its price of ₹15.90 on 04 November 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. Reported Earnings • Feb 03
Third quarter 2021 earnings released: EPS ₹1.94 (vs ₹1.30 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹25.3m (up 28% from 3Q 2020). Net income: ₹8.92m (up 49% from 3Q 2020). Profit margin: 35% (up from 30% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Ankündigung • Jan 23
Caprolactam Chemicals Limited to Report Q3, 2021 Results on Feb 02, 2021 Caprolactam Chemicals Limited announced that they will report Q3, 2021 results on Feb 02, 2021 Is New 90 Day High Low • Jan 07
New 90-day high: ₹19.55 The company is up 18% from its price of ₹16.60 on 09 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 23% over the same period. Reported Earnings • Nov 10
Second quarter 2021 earnings released: EPS ₹0.49 The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹14.6m (up 24% from 2Q 2020). Net income: ₹2.26m (up ₹2.44m from 2Q 2020). Profit margin: 15% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Sep 25
New 90-day low: ₹15.55 The company is down 29% from its price of ₹22.05 on 26 June 2020. The Indian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. Ankündigung • Sep 13
Caprolactam Chemicals Limited to Report Q1, 2021 Results on Aug 01, 2020 Caprolactam Chemicals Limited announced that they will report Q1, 2021 results on Aug 01, 2020 